Home Depot Q2 Earnings Miss Estimates, Comparable Sales Rise Y/Y
The Home Depot, Inc. Price, Consensus and EPS Surprise
The Home Depot, Inc. price-consensus-eps-surprise-chart | The Home Depot, Inc. Quote
Detailed Picture of HD's Q2 Results
Home Depot's adjusted earnings of $4.68 per share increased slightly by 0.2% from $4.67 in the year-ago quarter. However, the bottom line missed the Zacks Consensus Estimate of $4.71 per share.Net sales increased 4.9% to $45.3 billion from $43.2 billion in the year-ago quarter. However, sales lagged the Zacks Consensus Estimate of $45.5 billion.Home Depot's comparable sales increased 1% in the reported quarter. The company's comparable sales in the United States improved 1.4% in the fiscal second quarter. However, unfavorable foreign exchange rates reduced total company comparable sales by about 40 basis points in the quarter. Customer transactions were 446.8 million, down 0.9% year over year. Average ticket improved 1.2% year over year in the quarter under review.
HD's Costs & Margin Details
In dollar terms, gross profit rose 4.9% year over year to $15.1 billion in the fiscal second quarter. The gross margin was approximately 33.4%, roughly flat year over year. Our model predicted a 10-bps year-over-year decline in the gross margin to 33.3% for the fiscal second quarter.SG&A expenses of $7.8 billion increased 8.7% from $7.1 billion in the year-ago quarter; as a percentage of sales, SG&A was about 17.1%, up roughly 60 bps year over year.Operating income was $6.6 billion, up 0.3% year over year, while the operating margin of about 14.5% contracted by roughly 65 bps year over year.Our model predicted the SG&A expense rate to increase by 50 bps year over year to 17%. Consequently, we anticipated the operating income to increase 1.1% year over year and the operating margin to contract 60 bps to 14.5% for the fiscal second quarter.
HD Stock's Past 3-Month Performance
Image Source: Zacks Investment Research
HD's Other Financial Updates
Home Depot ended second-quarter fiscal 2025 with cash and cash equivalents of $2.8 billion, long-term debt (excluding current installments) of $45.9 billion and stockholders' equity of $10.7 billion. For the first six months of fiscal 2025, the company generated $9.0 billion of net cash from operating activities.
What Does HD Plan for FY25?
Management reiterated its sales and earnings per share view for fiscal 2025. Home Depot anticipates sales to increase 2.8% year over year. The company expects comparable sales to increase 1% for the 52 weeks.HD estimates the gross margin for fiscal 2025 to be 33.4%, with an operating margin of 13%. It expects an adjusted operating margin of 13.4%. HD plans to open 13 stores for fiscal 2025.Home Depot anticipates earnings per share to decline 3% year over year for fiscal 2025. It expects adjusted earnings per share to fall 2% year over year. The company anticipates capital expenditures to be 2.5% of total sales.This Zacks Rank #3 (Hold) company's shares have gained 4.7% in the past three months compared with the industry's 6.5% growth.
Stocks to Consider
Some better-ranked stocks are Somnigroup International Inc. SGI, Williams-Sonoma, Inc. WSM and Torrid Holdings Inc. CURV.Somnigroup is a bedding company that designs, manufactures, distributes and retails sleep solutions. It carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for Somnigroup's current financial-year sales and earnings indicates growth of 50.7% and a decline of 0.4%, respectively, from the previous year's figures. SGI has a trailing four-quarter average earnings surprise of 3.7%.Williams-Sonoma is a multi-channel specialty retailer of premium-quality home products. It currently carries a Zacks Rank #2. WSM has a trailing four-quarter earnings surprise of 8.8%, on average.The Zacks Consensus Estimate for Williams-Sonoma's current fiscal-year sales and earnings indicates growth of 0.1% and a decline of 3%, respectively, from the year-ago numbers.Torrid Holdings is a direct-to-consumer brand of apparel, intimates and accessories. It currently carries a Zacks Rank of 2.The Zacks Consensus Estimate for Torrid Holdings' current fiscal-year sales and earnings indicates a decline of 5.6% and 6.7%, respectively, from the year-ago numbers. CURV has a negative trailing four-quarter earnings surprise of 10.5%, on average.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Home Depot, Inc. (HD) : Free Stock Analysis Report
Williams-Sonoma, Inc. (WSM) : Free Stock Analysis Report
Somnigroup International Inc. (SGI) : Free Stock Analysis Report
Torrid Holdings Inc. (CURV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Guess?, Inc. (NYSE: GES) will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, on Wednesday, August 27, 2025. The financial results will be accessible at via the 'Investor Relations' link. In light of the pending take-private transaction announced separately today, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. At May 3, 2025, the Company directly operated 1,074 retail stores in Europe, the Americas and Asia. The Company's partners and distributors operated 527 additional retail stores worldwide. At May 3, 2025, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit
Business Wire
an hour ago
- Business Wire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27 th Annual Global Investment Conference in New York City, September 8-10, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. ('RenovoRx' or the 'Company') (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025. Mr. Bagai will be conducting a virtual presentation, which will be available for the duration of the conference, and afterwards on the Company's IR website at Mr. Bagai will discuss RenovoRx's ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai's presentation will also highlight the latest developments in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee's (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52 nd death. The TIGeR-PaC trial is evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC). Presentation Details: To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@ About RenovoCath Based on its FDA clearance, RenovoCath ® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ('IFU'), please see: About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner. For more information, visit Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company's management made in connection therewith and at the investor conference described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath ® or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as 'may,' 'expects,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'forecasts,' 'estimates,' 'intends,' and 'potential,' or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Yahoo
an hour ago
- Yahoo
Adia Med Expands Into Wound Care, Targeting High-Demand $25 Billion Market and Unlocking New Growth Avenues
Winter Park, Florida--(Newsfile Corp. - August 20, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company at the forefront of regenerative medicine and personalized health solutions, today announced that its clinical division, Adia Med, is officially expanding into the high-demand field of advanced wound care. This strategic move enables the company to serve a wider patient base, meet a critical and growing healthcare need, and open a new stream of revenue that supports long-term shareholder value. Every year, an estimated 8.2 million Americans require medical treatment for chronic wounds, including diabetic foot ulcers, pressure sores, post-surgical wounds, and injuries resulting from poor circulation. These conditions are particularly prevalent among older adults and individuals with diabetes or vascular disease. Of those patients, approximately 1.6 million undergo skin graft procedures annually as part of their treatment and recovery process. As the population ages and chronic diseases become more widespread, the demand for advanced wound care is expected to rise sharply over the next decade. The wound care market is valued at $25.84 billion in 2025 and is projected to reach $38.39 billion annually by 2034, according to industry analyses (Precedence Research, 2024, link). This includes hospital-based interventions, outpatient procedures, home health services, and advanced therapies. Insurance providers are increasingly incentivizing high-quality, outpatient wound care as a cost-effective alternative to hospitalization, creating a significant opportunity for providers like Adia Med to lead with innovative, patient-centered approaches. By entering this sector, Adia Med is responding directly to market demand while establishing a scalable revenue stream that aligns with its broader clinical strategy. The company will begin offering wound care services at its flagship Winter Park, Florida clinic, with plans to expand based on patient volume, clinical partnerships, and insurance approval. Services will include personalized wound evaluations, evidence-based protocols, and regenerative support therapies designed to accelerate healing, reduce complications, and improve patient outcomes. "This expansion into wound care is both a mission-driven and market-smart decision," said Larry Powalisz, CEO of Adia Nutrition Inc. "We're addressing a real and growing problem that impacts millions of people, while also adding a new layer of value for our shareholders. Wound care represents a stable, high-reimbursement category with strong insurance support and we're stepping in with the tools, talent, and strategy to do it right." Adia Med is currently in-network with major insurance providers including UnitedHealthcare and Aetna, positioning the company to make wound care services accessible and affordable for a large number of patients from day one. This move also reinforces Adia Med's commitment to integrated, whole-person care by adding a new service line that complements its existing wellness and regenerative health offerings. As the company continues to grow, wound care will serve as both a meaningful healthcare solution and a durable revenue vertical contributing to Adia Med's mission of expanding access, driving innovation, and delivering sustainable returns for investors. For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@ or by phone at 321-788-0850. Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
